Dengue Vaccine Sales Increased 863%

As the world confronts dengue fever outbreaks in over 100 countries, many are launching vaccination campaigns to reduce the impact of this mosquito-transmitted disease.

And a Japan-based company is benefiting from increased vaccine sales.

Takeda Pharmaceutical Company Limited today announced that its dengue vaccine QDENGA sales increased 863% in the FY2024 H1, reaching JPY 19.9 billion (~$124 million).

On October 31, 2024, Takeda's quarterly presentation revealed on slide #29, the following insights:

QDENGA is now available in 25 countries, including 18 European countries. Increasing breadth and depth in these markets and further expansion into Malaysia, Israel, and Vietnam in 2024.

Previously, the World Health Organization added QDENGA to its List of Prequalified Vaccines, and the Gavi Board recently approved support for a dengue vaccine program.

In the United States, where QDENGA is unavailable, the Centers for Disease Control and Prevention (CDC) has reported 6,819 travel-related and locally acquired dengue cases in 50 jurisdictions this year, led by California, Florida, New Jersey, New York, and Puerto Rico.

This CDC data indicates an 11% increase compared to 2023, when 6,164 dengue cases were reported.